Vtv Therapeutics Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Vtv Therapeutics has an operating margin of -2377.6%, meaning the company retains $-2378 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Vtv Therapeutics has a moderate D/E ratio of 1.96. This balance of debt and equity financing earns a leverage score of 38/100.
With a current ratio of 7.34, Vtv Therapeutics holds $7.34 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Vtv Therapeutics generated -$25.3M in operating cash flow, capex of $0 consumed most of it, leaving -$25.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Vtv Therapeutics passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Vtv Therapeutics generates $1.37 in operating cash flow (-$25.3M OCF vs -$18.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Vtv Therapeutics (VTVT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Vtv Therapeutics generated $1.0M in revenue in fiscal year 2024.
Vtv Therapeutics's EBITDA was -$24.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.2% from the prior year.
Vtv Therapeutics generated -$25.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 32.6% from the prior year.
Vtv Therapeutics reported -$18.5M in net income in fiscal year 2024. This represents an increase of 8.8% from the prior year.
Vtv Therapeutics held $36.7M in cash against $0 in long-term debt as of fiscal year 2024.
Vtv Therapeutics's operating margin was -2377.6% in fiscal year 2024, reflecting core business profitability.
Vtv Therapeutics's net profit margin was -1815.3% in fiscal year 2024, showing the share of revenue converted to profit.
Vtv Therapeutics invested $11.5M in research and development in fiscal year 2024. This represents a decrease of 15.1% from the prior year.
Vtv Therapeutics invested $0 in capex in fiscal year 2024, funding long-term assets and infrastructure.
VTVT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0-100.0% | $17K | $0-100.0% | $1.0M | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $7.0M+71.1% | $4.1M+45.0% | $2.8M+26.7% | $2.2M-35.0% | $3.4M+29.8% | $2.6M+23.9% | $2.1M-24.3% | $2.8M |
| SG&A Expenses | $3.7M+1.7% | $3.6M-1.5% | $3.7M+37.3% | $2.7M-28.0% | $3.7M-6.6% | $4.0M+54.8% | $2.6M+1.0% | $2.5M |
| Operating Income | -$10.7M-38.6% | -$7.7M-18.7% | -$6.5M-32.9% | -$4.9M+31.6% | -$7.2M-27.2% | -$5.6M-19.5% | -$4.7M+12.3% | -$5.4M |
| Interest Expense | $5K | N/A | N/A | $0 | $0 | N/A | $7K+75.0% | $4K |
| Income Tax | $0 | $0 | $0 | $0 | $0-100.0% | $100K | $0 | $0 |
| Net Income | -$8.7M-43.9% | -$6.0M-18.7% | -$5.1M-40.1% | -$3.6M+29.8% | -$5.2M-6.5% | -$4.9M-39.9% | -$3.5M+47.7% | -$6.7M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VTVT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $99.5M+276.2% | $26.4M-17.4% | $32.0M-16.3% | $38.3M-17.6% | $46.5M-14.3% | $54.2M+391.8% | $11.0M-26.2% | $14.9M |
| Current Assets | $99.5M+277.1% | $26.4M-17.4% | $31.9M-16.3% | $38.1M-17.5% | $46.2M-14.2% | $53.9M+405.5% | $10.7M+5.3% | $10.1M |
| Cash & Equivalents | $98.5M+280.0% | $25.9M-16.5% | $31.1M-15.5% | $36.7M-19.3% | $45.5M-12.9% | $52.3M+453.2% | $9.4M+14.7% | $8.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | $62K-79.7% | $306K-68.8% | $981K+861.8% | $102K | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $29.0M+20.4% | $24.0M+3.9% | $23.1M-3.5% | $24.0M-7.9% | $26.0M-7.7% | $28.2M-21.0% | $35.7M-11.1% | $40.2M |
| Current Liabilities | $10.2M+91.9% | $5.3M+22.7% | $4.3M-16.9% | $5.2M-25.6% | $7.0M-21.7% | $8.9M-16.0% | $10.6M+3.3% | $10.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $70.5M+2454.1% | $2.8M-65.1% | $7.9M-35.1% | $12.2M-26.0% | $16.5M-20.8% | $20.8M+184.3% | -$24.7M+2.2% | -$25.2M |
| Retained Earnings | -$319.6M-2.8% | -$310.9M-2.0% | -$304.8M-1.7% | -$299.7M-2.9% | -$291.3M-1.8% | -$286.1M-1.8% | -$281.0M+0.1% | -$281.2M |
VTVT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.2M-2.5% | -$5.1M+10.4% | -$5.7M-17.9% | -$4.8M+28.3% | -$6.7M+8.3% | -$7.3M-151.7% | -$2.9M+39.7% | -$4.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$2.9M+39.7% | -$4.8M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $4.4M | $0 |
| Financing Cash Flow | $77.8M+185347.6% | -$42K | $0 | $0 | $0-100.0% | $50.1M+17881.6% | -$282K-159.6% | $473K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VTVT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | -28776.5% | N/A | -562.7% | N/A | N/A |
| Net Margin | N/A | N/A | N/A | -21376.5% | N/A | -486.5% | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8.7%+14.1pp | -22.9%-7.0pp | -15.9%-6.4pp | -9.5%+1.7pp | -11.2%-2.2pp | -9.0%+22.6pp | -31.6%+13.0pp | -44.6% |
| Current Ratio | 9.79+4.8 | 4.98-2.4 | 7.39+0.1 | 7.34+0.7 | 6.61+0.6 | 6.04+5.0 | 1.00+0.0 | 0.99 |
| Debt-to-Equity | 0.41-8.3 | 8.70+5.8 | 2.92+1.0 | 1.96+0.4 | 1.58+0.2 | 1.36+2.8 | -1.45+0.1 | -1.59 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Vtv Therapeutics's annual revenue?
Vtv Therapeutics (VTVT) reported $1.0M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Vtv Therapeutics profitable?
No, Vtv Therapeutics (VTVT) reported a net income of -$18.5M in fiscal year 2024, with a net profit margin of -1815.3%.
What is Vtv Therapeutics's EBITDA?
Vtv Therapeutics (VTVT) had EBITDA of -$24.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Vtv Therapeutics's operating margin?
Vtv Therapeutics (VTVT) had an operating margin of -2377.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Vtv Therapeutics's net profit margin?
Vtv Therapeutics (VTVT) had a net profit margin of -1815.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Vtv Therapeutics's free cash flow?
Vtv Therapeutics (VTVT) generated -$25.3M in free cash flow during fiscal year 2024. This represents a -32.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Vtv Therapeutics's operating cash flow?
Vtv Therapeutics (VTVT) generated -$25.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Vtv Therapeutics's total assets?
Vtv Therapeutics (VTVT) had $38.3M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Vtv Therapeutics's capital expenditures?
Vtv Therapeutics (VTVT) invested $0 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Vtv Therapeutics spend on research and development?
Vtv Therapeutics (VTVT) invested $11.5M in research and development during fiscal year 2024.
What is Vtv Therapeutics's current ratio?
Vtv Therapeutics (VTVT) had a current ratio of 7.34 as of fiscal year 2024, which is generally considered healthy.
What is Vtv Therapeutics's debt-to-equity ratio?
Vtv Therapeutics (VTVT) had a debt-to-equity ratio of 1.96 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Vtv Therapeutics's return on assets (ROA)?
Vtv Therapeutics (VTVT) had a return on assets of -48.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Vtv Therapeutics's cash runway?
Based on fiscal year 2024 data, Vtv Therapeutics (VTVT) had $36.7M in cash against an annual operating cash burn of $25.3M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Vtv Therapeutics's Piotroski F-Score?
Vtv Therapeutics (VTVT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Vtv Therapeutics's earnings high quality?
Vtv Therapeutics (VTVT) has an earnings quality ratio of 1.37x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Vtv Therapeutics?
Vtv Therapeutics (VTVT) scores 35 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.